ADMA stock news today

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

ADMA Biologics CEO comments on ASCENIV's future

The chief executive of ADMA Biologics spoke about the company's product ASCENIV. The remarks suggest the company sees more ahead for the treatment.

Cantor Fitzgerald keeps Neutral rating on ADMA Biologics, lifts price target

Cantor Fitzgerald repeated its Neutral rating on ADMA Biologics while raising its price target on the shares. The change reflects the firm's updated view of the stock.

Mizuho Securities set a price target of $18 on ADMA Biologics (ADMA).

Cantor Fitzgerald keeps Neutral rating on ADMA Biologics, lifts target to $13

Cantor Fitzgerald stayed Neutral on ADMA Biologics while raising its price target to $13. The change reflects the firm's updated view on the stock.

ADMA Biologics stock rises 28% in after-hours trading

ADMA Biologics shares gained 28% after the regular session closed. The headline gives no stated reason for the move.

ADMA Biologics Posts Q3 2026 Results

The company released its quarterly financial figures for the three months ended in 2026. The filing covers its performance over that span.

ADMA Biologics holds Q3 2026 earnings call

ADMA Biologics discussed its third-quarter 2026 results on an earnings call. The transcript covers the company's quarterly performance.

ADMA Biologics forecasts FY2026 revenue above $530 million

ADMA Biologics expects fiscal 2026 revenue to exceed $530 million. That figure falls short of the $535.36 million estimate.

ADMA Biologics Q3 profit and revenue top analyst estimates

ADMA Biologics posted third-quarter adjusted earnings of $0.23 per share, above the $0.20 consensus. Revenue came in at $141.102 million, also exceeding the $138.190 million estimate.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

ADMA Biologics announces journal publication on IVIG production method

ADMA Biologics said new findings tied to its improved, proprietary way of making intravenous immune globulin appeared in a peer-reviewed cardiovascular journal. Shares moved up following the news.

ADMA Biologics reports three-lot study of updated IVIG process

ADMA Biologics said a three-lot study found its updated IVIG manufacturing process removes clot-linked impurities and raises yield. No clotting events were reported through July 2026.

What is the latest news on ADMA?

Nov 5, 2026: Adma Biologics, Inc. filed an insider trading report (Form 4) (SEC) · Nov 5, 2026: ADMA Biologics CEO comments on ASCENIV's future (Benzinga) · Nov 5, 2026: Cantor Fitzgerald keeps Neutral rating on ADMA Biologics, lifts price target (Fiscal.ai)

What are analysts saying about ADMA?

Nov 5, 2026: Mizuho Securities set a price target of $18 on ADMA Biologics (ADMA).

What has ADMA filed with the SEC recently?

Nov 5, 2026: Adma Biologics, Inc. filed an insider trading report (Form 4) · Nov 4, 2026: Adma Biologics, Inc. filed a report on a major company event (Form 8-K)